AstraZeneca to sell five hypertension drugs to Atnahs Pharma
AstraZeneca has signed a deal valued at about $390 million with Atnahs Pharma, a portfolio company of Triton Fund V, to sell five of its hypertension drugs to the latter as they have lost patent protection across the world. The deal will give Atnahs Pharma the global commercial rights to the hypertension medicines – Inderal (propranolol), […]